Where to buy capmatinib
Capmatinib (Capmatinib) is a MET-targeted kinase inhibitor indicated as monotherapy for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) who harbor alterations leading to mesenchymal epithelial transition factor gene (MET) exon 14 (METex14) skipping and who require systemic therapy prior to immunotherapy and/or platinum-based chemotherapy.

Aberrant activation of c-Met has been demonstrated in many cancers, including non-small cell lung cancer. Mutations that cause METex14 skipping result in mutant proteins lacking regulatory domains that have reduced negative regulatory capacity, resulting in a pathological increase in their downstream activity. Capmatinib inhibits the phosphorylation of c-Met wild-type and mutant variants triggered by binding of the endogenous ligand hepatocyte growth factor, thereby preventing c-Met-mediated phosphorylation of downstream signaling proteins and the proliferation and survival of c-Met-dependent tumor cells.
The original drug Capmatinib has not yet been launched in China, so it has not been included in the medical insurance. However, in Hong Kong, each box of the drug has a price tag of more than 30,000 yuan (the price may fluctuate due to the exchange rate) for a box of 200mg*60 tablets (the price may fluctuate due to exchange rates), and this drug may be sold in local hospitals or pharmacies.
In overseas markets, the European versionThe price of each box of the original drug in 200 mg and 120 doses exceeds RMB 50,000, which may also fluctuate due to exchange rates. However, there are also more affordable generic capmatinib drugs available overseas. The ingredients of the drug are basically the same as those of the original drug. For example, the price of a 200mg*56 tablet drug produced in Laos may only cost more than 3,000 yuan per box. Although it may also be affected by the exchange rate, it has been greatly reduced compared to the original drug. For more information on overseas drug prices and related information, please consult Yaode Medical Consultants.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)